Cervical cancer and human papillomavirus: South African guidelines for screening and testing
Abstract
Cervical carcinoma is still the most common cancer of women \non the African continent. Mortality remains high – worldwide at \n50% – mainly because of late presentation, advanced stage of \ndisease and absence of a functioning screening process. The \naetiological link between human papillomavirus (HPV) infection \nand cervical cancer has been well established and a number of \nhigh-risk HPV genotypes have been identified. HPV infection is \nthe most common sexually transmitted infection (STI) in the world \ntoday – up to 80% of sexually active females will harbour HPV at \nsome point in their lives. The majority of women will experience \nnatural elimination of HPV infection because of an intact immune \nsystem. Persistent infection with a high risk type HPV puts women \nat high risk to develop precursors of cervical cancer or carcinoma \nitself. As part of a public health response to this serious problem, \nseveral HPV vaccines are under development. Use of vaccines still \nposes unanswered questions in many respects.
